This review discusses metabolic engineering strategies to boost mevalonate yield in microorganisms, emphasizing yeast and E. coli.
Mevalonate (MVA), a pivotal precursor in the biosynthesis of terpenoids, exhibits substantial application value in fields such as food, medicine, and materials, with both MVA itself and its derivatives demonstrating significant biological activity and application value. This review systematically summarizes the advancements in MVA biosynthesis, with a particular focus on metabolic engineering strategies employed in microorganisms including yeast, Escherichia coli, Pseudomonas putida, and Methylobacterium extorquens. These strategies encompass optimizing the expression of key enzymes, enhancing the supply of precursors like acetyl-CoA, blocking competitive metabolic pathways, and constructing dynamic regulatory systems. Through the metabolic engineering strategies and optimization of fermentation conditions, the MVA yields of various engineered strains have been significantly improved. Prospects of microbial MVA production are also considered.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: